Effect of Anagliptin on Glycemic and Lipid Profile in Patients With Type 2 Diabetes Mellitus
| Autor: | Daisuke Suzuki, Yasuo Terauchi, Mizuki Kaneshiro, Hiroshi Shigematsu, Hirosuke Danno, Mari S. Oba, Yukari Chiba, Yoji Takatsuka, Hirohisa Tsuchiya, Tadashi Yamakawa |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
Type 2 diabetes Dipeptidyl peptidase-4 inhibitor 030204 cardiovascular system & hematology Gastroenterology 03 medical and health sciences 0302 clinical medicine Internal medicine Type 2 diabetes mellitus medicine Low-density lipoprotein cholesterol In patient Total cholesterol Glycemic medicine.diagnostic_test business.industry Anagliptin Type 2 Diabetes Mellitus Lipid metabolism General Medicine medicine.disease 030220 oncology & carcinogenesis Original Article lipids (amino acids peptides and proteins) Lipid profile business medicine.drug |
| Zdroj: | Journal of Clinical Medicine Research |
| ISSN: | 1918-3011 1918-3003 |
| DOI: | 10.14740/jocmr3464w |
| Popis: | Background: Anagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor expected to improve the lipid profile as well as glycemic control. However, findings from large-scale prospective trials have not been obtained. Methods: We performed a multicenter prospective trial in patients with type 2 diabetes receiving anagliptin to evaluate its effect on glycemic control and the lipid profile. A total of 95 patients received anagliptin at 200 mg twice daily. Markers of glucose and lipid metabolism were measured at baseline and after 12 and 24 weeks of administration, and the absolute changes and percent changes were determined. Results: Both HbA1c and plasma glucose were significantly decreased by anagliptin therapy. Regarding the lipid profile, total cholesterol (TC) showed a significant decrease at 12 weeks, while TC, low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) were significantly decreased at 24 weeks. Multivariate analysis revealed that female sex was an independent predictor of greater reduction of TC, LDL-C, and HDL-C, while a baseline TC level ≥ 200 mg/dL predicted greater reduction of TC and a baseline HDL-C level ≥ 40 mg/dL predicted greater reduction of LDL-C and HDL-C. Conclusions: This study suggested that anagliptin significantly reduced TC, LDL-C, and HDL-C levels, as well as improving glycemic control, particularly in female patients. J Clin Med Res. 2018;10(8):648-656 doi: https://doi.org/10.14740/jocmr3464w |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|